A New Supplement Paradigm: GLP-1 Agonists and Chromax® Chromium Picolinate

Published on June 26, 2024 by Mike Roberto | No Comments

Unless you’ve been in a long coma, you’ve undoubtedly heard of Ozempic.

Ozempic is Here… and Here to Stay for a While

Scientifically known as semaglutide, Ozempic is a drug that’s taken the world by storm, chiefly because of its successful weight management results. Originally developed to manage type-2 diabetes, it’s in a class of prescription drugs known as GLP-1 receptor agonists. This also includes Wegovy, an injectable drug that is approved for use as a weight loss medication in obese patients.[1]

Chromax Chromium Picolinate GLP-1 Agonists (Semaglutide)

We’re entering a new paradigm of dietary supplementation, with a goal of losing fat, not muscle. Regardless of your use of GLP-1 drugs or not, Chromax® Chromium Picolinate has a great place in every healthy person’s life!

While these medications show promise for weight loss, they’re not a panacea, and dieters should always consider all health avenues, whether or not a GLP-1 agonist drug is used. This includes diet, exercise, and supplements to fill nutritional gaps.

Savvy consumers and dietary supplement brands must keep this in mind when developing supplement stacks and products to support weight and health goals — users of GLP-1 medications represent a new and growing demographic in the market to assist.

Consider Chromax®

In this article, we explore one ingredient that should be considered in supplement stacks and formulations: Nutrition21’s Chromax®, which is the industry’s premier form of chromium (as chromium picolinate). Chromax has demonstrated an ability to:

  • Help maintain muscle when losing weight and support overall body composition
  • Support carbohydrate metabolism and insulin function, and
  • Help manage cravings and appetite.

Regardless of a dieter’s decision to take a pharmaceutical approach to weight loss, these are all great benefits to pursue.

Let’s look at some of the recent research on these drugs, and see if there’s a connection to be made with chromium supplementation:

2024 Research review: Semaglutide and Lean Mass Loss

The news surrounding GLP-1 agonists has highlighted many of their positive and negative effects, reinforcing the stance that diet, exercise, and supplementation need to be considered in all situations.

In recent weeks, new reports of Ozempic’s side effects have emerged, which can be summarized succinctly by reference to the Atlantic’s headline proclaiming that “Ozempic Makes You Lose More Than Fat”.[2] Unfortunately, it seems that treatment with this drug can cause significant amounts of muscle loss, as explored by an April 2024 systematic research review investigating six separate studies.[3]

Still – the same review found that even in larger trials where the reduction in lean mass was more evident, semaglutide treatment increased the study subjects’ proportion of lean mass, indicating a net improvement to overall body composition.[3]

Whether this makes Ozempic “worth it” for any given dieter is highly dependent on that person’s individual context. Some people can maintain a high-protein diet with resistance training, which may stave off many of these effects. Others also have more muscle mass to begin with. So, as always, you should ask your doctor if these findings may relate to you.

GLP-1 Agonists aren’t going anywhere, but there are issues to consider

Ozempic has become a handy signifier for the entire category of drugs, which is based on its primary mechanism of action, glucagon-like peptide 1 (GLP-1) agonism. These are drugs that increase the expression of GLP-1, which enhances insulin secretion, improves blood glucose control, and promotes satiety by slowing gastric emptying,[4-9] thereby aiding in the management of diabetes and obesity.

With the improvement of satiety comes the reduction of appetite, and thus, food intake. This can lead to nutritional gaps, and that’s exactly where dietary supplements fit in — from protein to fiber to essential minerals.

The question becomes, how can we support dieters’ effectiveness and prevent issues from reduced food consumption?

  • Keep protein high

    Podium HWPO Whey Isolate Protein

    Powered by Nutrition21’s Velositol, Podium Nutrition’s HWPO Whey Isolate Protein makes hard work pay off even more!

    The first idea that comes to mind is protein and essential amino acid supplementation. Since high-protein diets have been shown to support body composition with nearly every dietary tactic,[10-14] it’s imperative to keep the critical macronutrient high, support as much muscle mass as possible. Protein shakes can certainly support these goals.[15-19]

    For example, a protein powder we’ve recently covered that keeps the fats, calories, and carbs lower with the protein still high is Podium Nutrition’s HWPO Whey Isolate. Even someone whose appetite is a bit lower can appreciate a quick shake like this, keeping amino acids circulating, supporting muscle tissue.

  • Don’t forget the healthy fats

    Dieters with lower appetites are likely to be dropping added fats, as well. This is a great opportunity to re-balance the omega-3:omega-6 ratio, which was historically closer to 1:1 before the industrialization of food.[20-23] Higher omega-6 ratios are predictive of cardiovascular disease,[20,24] insulin resistance and metabolic dysfunction,[25-28] diabetes,[29-31] and obesity.[32-34]

    So the goal here is to reduce the industrial omega-6 fats, and boost omega-3 fatty acids, which have been shown to support critical metabolic biomarkers.[35-39]

  • Consider fiber

    Fiber supplementation is often situation-dependent, but in general, there are an incredible number of benefits to its supplementation.[40]

    Aside from supporting the gut microbiome,[41] fiber has been shown to improve insulin sensitivity and overall metabolic health improvements[42] while supporting healthy weight and abdominal fat reduction.[43,44] It also improves gut motility and prevents constipation,[45] which could greatly help this new generation of dieters.

    Chromax Chromium Picolinate: Lose the Fat, Not the Muscle

    Goals

    However, not everyone responds incredibly well to fiber, so it’s worth putting into a separate formula and allowing the right consumers to use it.

  • Resistance train!

    We’d also be remiss to mention resistance training, which supports the development and maintenance of skeletal muscle, especially when in a positive nitrogen environment (eg. keep protein intake high).[46] Dieters don’t need to be breaking world records or accomplishing Olympic lifts, but they should work to get their muscles to respond to stimulus.

Beyond the initial ideas of protein and fiber, however, vitamin and mineral intake may not be adequate, and this is where supplementation comes in. And one mineral in particular aligns extraordinarily well with diet.

Chromax Chromium – Great For Diet, Health, and Body Composition

Whenever anyone reduces their overall caloric intake — whether it’s from GLP-1 use or not — there are additional steps beyond protein intake that should be considered. A prime candidate is Chromax (chromium picolinate) from Nutrition 21.

  • Supports insulin signaling

    GLP-1 agonists are insulinogenic, which is actually not always a bad thing. As it turns out, these drugs only increase insulin secretion when blood glucose levels rise, which is why they can help decrease postprandial hyperglycemia without having an adverse effect on baseline insulin levels.[47]

    Chromax

    For over 25 years, Chromax chromium picolinate has been improving insulin sensitivity. We argue that it’s only gotten better, as dietary mineral deficiencies have gotten worse over this time period.

    Still, in order to optimize metabolic health, we want the body to use insulin as efficiently as possible, and that’s where Chromax comes in.

    Ingested chromium binds to a low-molecular-weight peptide complex referred to as low-molecular-weight chromium-binding substance (LMWCr). This complex is composed of several amino acids that can chelate chromium ions, forming the active complex known as chromodulin.[48,49]

    Though the exact mechanism through which chromium impacts insulin is still unknown, one mechanism is thought to relate to this chromium-chromodulin interaction. One study found that chromodulin activates the insulin receptor,[50] in a manner that roughly approximates insulin itself – but it also amplifies the effect of circulating insulin. One in vitro study has found that chromodulin can increase insulin’s signaling activity by an incredible 800%.[50] And when it comes to stimulating chromodulin activity, chromium is in a class of its own – there is no other mineral that’s been shown to have a similar effect on chromodulin.[51]

    Thus, Chromax can potentially lead to a positive effect on promoting a healthy insulin response, and we suspect it will be for numerous types of dieters, regardless of their choice on GLP-1 drugs.

  • Insulin Resistance, High-Sugar Diets, Stress, and Chromium Availability

    N21 Chromax Weight Loss Graph

    Chromax helps you ditch the fat but keep the muscle! Image courtesy of Nutrition21.

    Data shows that individuals with severe insulin resistance have lower chromium levels, as measured in hair, sweat, and serum.[52] Additional research has found that those with diets high in sugar may have depleted chromium levels, since its excretion is elevated in those dietary circumstances.[53] Other circumstances, such as those who are chronically stressed or exercise too little also have increased excretion of chromium.[54] While not causal, these data suggest a relationship between carbohydrate metabolism and chromium.

  • Appetite Suppression

    Other evidence suggests that Chromax could support healthy appetite in dieters.

    For example, in one randomized, double-blind, placebo-controlled study from 2008, researchers administered Chromax® chromium picolinate to overweight women. For eight weeks, they received either 1,000 mcg of chromium, or a placebo, while each group’s caloric intake was tracked.

    By the end of the study period, the Chromax® group exhibited significantly less food intake, decreased hunger levels, and more specifically, lower cravings for dietary fat.[55] The Chromax group also showed decreased body weight – while the placebo group gained about a pound of weight, the Chromax group lost about the same amount.[55] While these aren’t massive changes in weight, the inclusion of Chromax chromium picolinate helped manage aspects of appetite which may have helped to support some weight loss.

    Chromium Picolinate Appetite

    In this study, overweight women who took chromium reduced their food intake by significantly more than the placebo group..[55]

    Another, earlier randomized double-blind study, published in 2005, administered either 600 mcg chromium as Chromax chromium picolinate or a placebo to 113 adults with atypical depression. It showed that chromium ingestion was associated with significant reductions in appetite, food intake, and carbohydrate cravings, compared to the placebo.[56]

    It’s interesting to note that the first study showed lower cravings for dietary fat,[55] while the second showed reduced carbohydrate cravings.[56] Either direction may support the needle for higher protein intake, which is one of our primary goals for health and body composition.

    Both of these effects are more heavily covered in our article titled “Chromax and Hunger Regulation: The Chromium / Appetite Connection“. Ultimately, managing cravings and appetite while dieting can be very difficult for some — and Chromax may help.

Why Chromax?

Of course, if a dieter were to consider chromium supplementation, one would want to choose the best form of chromium available, and existing research indicates that the best is Chromax from Nutrition21. Two different peer-reviewed studies have demonstrated that Chromax is as much as 15 times more bioavailable than other types of chromium.[57,58]

Dosage: 1000 micrograms for appetite reduction

Chromax Carb Cravings

Chromium picolinate has been shown to reduce carbohydrate cravings![56]

In terms of dosage, Chromax has been studied in dose ranges providing 200 micrograms to 1000 micrograms of elemental chromium. The two studies showing reductions in cravings provided 600 and 1000 micrograms of chromium,[55,56] so we generally opt for the higher doses in these applications.

Subscribe to PricePlow on YouTube!

Conclusion: Either Way, Chromax Has a Place

GLP-1 medications have various clinical benefits and have been shown to help manage appetite. Whether taking these drugs or trying to manage your health through diet and exercise alone, chromium supplementation may help dieters achieve their health goals by promoting healthy body composition, supporting nutrient metabolism via effects on insulin, and even by helping manage cravings.

Backed by over 25 years of research, Chromax — which is made in the USA — has a great place in the health routines of dieters worldwide.

You can read more in our articles titled “Chromium Picolinate: The Ultimate Trace Mineral For Insulin Sensitivity“ and “Chromax Chromium Picolinate: 25+ Years of Insulin Sensitivity Improvement“, and sign up for our Nutrition21 news alerts below:

Subscribe to PricePlow's Newsletter and Alerts on These Topics

Topic Blog Posts YouTube Videos Instagram Posts
Chromax
GLP-1
Nutrition21

About the Author: Mike Roberto

Mike Roberto

Mike Roberto is a research scientist and water sports athlete who founded PricePlow. He is an n=1 diet experimenter with extensive experience in supplementation and dietary modification, whose personal expertise stems from several experiments done on himself while sharing lab tests.

Mike's goal is to bridge the gap between nutritional research scientists and non-academics who seek to better their health in a system that has catastrophically failed the public. Mike is currently experimenting with a low Vitamin A diet.

No Comments | Posted in , | Tagged , , , , , , , , , , .

References

  1. “Wegovy (Semaglutide) Information for Patients.” Drugs.com. https://www.drugs.com/wegovy.html
  2. Zhang, Sarah. “Ozempic Makes You Lose More than Fat.” The Atlantic, 2 Feb. 2024. https://www.theatlantic.com/health/archive/2024/02/ozempics-muscle-loss-problem/677326/
  3. Bikou, Alexia, et al. “A Systematic Review of the Effect of Semaglutide on Lean Mass: Insights from Clinical Trials.” Expert Opinion on Pharmacotherapy, 17 Apr. 2024, doi:10.1080/14656566.2024.2343092. https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2343092
  4. Kalas, M Ammar, et al. “Medication-Induced Gastroparesis: A Case Report.” Journal of Investigative Medicine High Impact Case Reports, vol. 9, Jan. 2021, p. 232470962110519, doi:10.1177/23247096211051919. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/
  5. Chaudhry, Ahtshamullah, et al. “Tendency of Semaglutide to Induce Gastroparesis: A Case Report.” Cureus, vol. 16, no. 1, 1 Jan. 2024, p. e52564, doi:10.7759/cureus.52564. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874596/
  6. Dahl, Kirsten, et al. “Oral Semaglutide Improves Postprandial Glucose and Lipid Metabolism, and Delays Gastric Emptying, in Subjects with Type 2 Diabetes.” Diabetes, Obesity and Metabolism, vol. 23, no. 7, 29 Mar. 2021, pp. 1594–1603, doi:10.1111/dom.14373. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251575/
  7. Horowitz, Michael, et al. “Glucagon-like Peptide-1 Receptor Agonists and the Appropriate Measurement of Gastric Emptying.” Diabetes, Obesity & Metabolism, vol. 22, no. 12, 1 Dec. 2020, pp. 2504–2506, doi:10.1111/dom.14166. https://pubmed.ncbi.nlm.nih.gov/32749029/
  8. Hjerpsted, Julie B., et al. “Semaglutide Improves Postprandial Glucose and Lipid Metabolism, and Delays First-Hour Gastric Emptying in Subjects with Obesity.” Diabetes, Obesity and Metabolism, vol. 20, no. 3, 27 Oct. 2017, pp. 610–619, doi:10.1111/dom.13120. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/
  9. Urva, Shweta, et al. “The Novel Dual Glucose‐Dependent Insulinotropic Polypeptide and Glucagon‐like Peptide‐1 ( GLP ‐1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long‐Acting GLP ‐1 Receptor Agonists.” Diabetes, Obesity and Metabolism, vol. 22, no. 10, 13 July 2020, pp. 1886–1891, doi:10.1111/dom.14110. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539915/
  10. Parker, B., et al. “Effect of a High-Protein, High-Monounsaturated Fat Weight Loss Diet on Glycemic Control and Lipid Levels in Type 2 Diabetes.” Diabetes Care, vol. 25, no. 3, 1 Mar. 2002, pp. 425–430, doi:10.2337/diacare.25.3.425. https://diabetesjournals.org/care/article/25/3/425/21929/Effect-of-a-High-Protein-High-Monounsaturated-Fat
  11. Noakes, Manny, et al. “Effect of an Energy-Restricted, High-Protein, Low-Fat Diet Relative to a Conventional High-Carbohydrate, Low-Fat Diet on Weight Loss, Body Composition, Nutritional Status, and Markers of Cardiovascular Health in Obese Women.” The American Journal of Clinical Nutrition, vol. 81, no. 6, 1 June 2005, pp. 1298–1306, doi:10.1093/ajcn/81.6.1298. https://www.sciencedirect.com/science/article/pii/S0002916523277126
  12. Evans, Ellen M, et al. “Effects of Protein Intake and Gender on Body Composition Changes: A Randomized Clinical Weight Loss Trial.” Nutrition & Metabolism, vol. 9, 12 June 2012, p. 55, doi:10.1186/1743-7075-9-55. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407769/
  13. Leidy, Heather J, et al. “The Role of Protein in Weight Loss and Maintenance.” The American Journal of Clinical Nutrition, vol. 101, no. 6, 29 Apr. 2015, pp. 1320S1329S, doi:10.3945/ajcn.114.084038. https://www.sciencedirect.com/science/article/pii/S0002916523274274
  14. S, Soenen, et al. “Relatively High-Protein or “Low-Carb” Energy-Restricted Diets for Body Weight Loss and Body Weight Maintenance?” Physiology & Behavior, 10 Oct. 2012. https://pubmed.ncbi.nlm.nih.gov/22935440
  15. Wirunsawanya, Kamonkiat, et al. “Whey Protein Supplementation Improves Body Composition and Cardiovascular Risk Factors in Overweight and Obese Patients: A Systematic Review and Meta-Analysis.” Journal of the American College of Nutrition, vol. 37, no. 1, 31 Oct. 2017, pp. 60–70, doi:10.1080/07315724.2017.1344591. https://pubmed.ncbi.nlm.nih.gov/29087242/
  16. Carbone, John W, and Stefan M Pasiakos. “Dietary Protein and Muscle Mass: Translating Science to Application and Health Benefit.” Nutrients vol. 11,5 1136. 22 May. 2019, doi:10.3390/nu11051136; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566799/
  17. Lemon, P W, et al. “Protein Requirements and Muscle Mass/Strength Changes during Intensive Training in Novice Bodybuilders.” Journal of Applied Physiology (Bethesda, Md. : 1985), vol. 73, no. 2, 1992, pp. 767–75, doi:10.1152/jappl.1992.73.2.767. https://pubmed.ncbi.nlm.nih.gov/1400008/
  18. Sm, Phillips, and Van Loon Lj. “Dietary Protein for Athletes: From Requirements to Optimum Adaptation.” Journal of Sports Sciences, 2011. doi:10.1080/02640414.2011.619204. https://pubmed.ncbi.nlm.nih.gov/22150425/
  19. Wu, Guoyao. “Dietary Protein Intake and Human Health.” Food & Function, vol. 7, no. 3, 11 Jan. 2016, pp. 1251–1265, doi:10.1039/c5fo01530h. https://pubmed.ncbi.nlm.nih.gov/26797090/
  20. Simopoulos, Artemis P. “The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases.” Experimental Biology and Medicine (Maywood, N.J.), vol. 233, no. 6, 2008, pp. 674–88, 10.3181/0711-MR-311; https://pubmed.ncbi.nlm.nih.gov/18408140/
  21. Eaton, S.B., et al. “Dietary Intake of Long-Chain Polyunsaturated Fatty Acids during the Paleolithic.” World Review of Nutrition and Dietetics, 1998, pp. 12–23, 10.1159/000059672; https://pubmed.ncbi.nlm.nih.gov/9648501/
  22. Crawford, M.A. “Fatty-Acid Ratios in Free-Living and Domestic Animals.” The Lancet, vol. 291, no. 7556, June 1968, pp. 1329–1333, 10.1016/s0140-6736(68)92034-5; https://www.sciencedirect.com/science/article/abs/pii/S0140673668920345
  23. Crawford, M A, et al. “Linoleic Acid and Linolenic Acid Elongation Products in Muscle Tissue of Syncerus Caffer and Other Ruminant Species.” Biochemical Journal, vol. 115, no. 1, 1 Oct. 1969, pp. 25–27, 10.1042/bj1150025; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1185064/
  24. Kromhout, Daan, and Janette de Goede. “Update on Cardiometabolic Health Effects of ω-3 Fatty Acids.” Current Opinion in Lipidology, vol. 25, no. 1, Feb. 2014, pp. 85–90, 10.1097/mol.0000000000000041; https://pubmed.ncbi.nlm.nih.gov/24345990/
  25. Tsitouras, P., et al. “High Omega-3 Fat Intake Improves Insulin Sensitivity and Reduces CRP and IL6, but Does Not Affect Other Endocrine Axes in Healthy Older Adults.” Hormone and Metabolic Research, vol. 40, no. 3, Mar. 2008, pp. 199–205, 10.1055/s-2008-1046759; https://pubmed.ncbi.nlm.nih.gov/18348080/
  26. Maki, Kevin C., et al. “Prescription Omega-3-Acid Ethyl Esters Reduce Fasting and Postprandial Triglycerides and Modestly Reduce Pancreatic β-Cell Response in Subjects with Primary Hypertriglyceridemia.” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 85, no. 3-4, Sept. 2011, pp. 143–148, 10.1016/j.plefa.2011.06.005; https://pubmed.ncbi.nlm.nih.gov/21775113/
  27. Simopoulos, Artemis. “Dietary Omega-3 Fatty Acid Deficiency and High Fructose Intake in the Development of Metabolic Syndrome, Brain Metabolic Abnormalities, and Non-Alcoholic Fatty Liver Disease.” Nutrients, vol. 5, no. 8, 26 July 2013, pp. 2901–2923, 10.3390/nu5082901; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775234/
  28. Fedor, Dawn, and Darshan S. Kelley. “Prevention of Insulin Resistance by N-3 Polyunsaturated Fatty Acids.” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 2, 1 Mar. 2009, pp. 138–146, 10.1097/MCO.0b013e3283218299; https://pubmed.ncbi.nlm.nih.gov/19202385/
  29. Huang, Tao, et al. “Plasma Phospholipids N-3 Polyunsaturated Fatty Acid Is Associated with Metabolic Syndrome.” Molecular Nutrition & Food Research, vol. 54, no. 11, 1 Nov. 2010, pp. 1628–1635, 10.1002/mnfr.201000025; https://pubmed.ncbi.nlm.nih.gov/20540149/
  30. Lauretani, F., et al. “Omega-3 and Renal Function in Older Adults.” Current Pharmaceutical Design, vol. 15, no. 36, 2009, pp. 4149–4156, 10.2174/138161209789909719; https://pubmed.ncbi.nlm.nih.gov/20041816/
  31. Huang, Tao, et al. “Increased Plasma N-3 Polyunsaturated Fatty Acid Is Associated with Improved Insulin Sensitivity in Type 2 Diabetes in China.” Molecular Nutrition & Food Research, vol. 54 Suppl 1, 1 May 2010, pp. S112-119, 10.1002/mnfr.200900189; https://pubmed.ncbi.nlm.nih.gov/19998382/
  32. Ramel, A., et al. “Beneficial Effects of Long-Chain N-3 Fatty Acids Included in an Energy-Restricted Diet on Insulin Resistance in Overweight and Obese European Young Adults.” Diabetologia, vol. 51, no. 7, 20 May 2008, pp. 1261–1268, 10.1007/s00125-008-1035-7; https://pubmed.ncbi.nlm.nih.gov/18491071/
  33. Simopoulos, Artemis. “An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity.” Nutrients, vol. 8, no. 3, 2 Mar. 2016, p. 128, 10.3390/nu8030128; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808858/
  34. Donahue, Sara MA, et al. “Prenatal Fatty Acid Status and Child Adiposity at Age 3 Y: Results from a US Pregnancy Cohort.” The American Journal of Clinical Nutrition, vol. 93, no. 4, 10 Feb. 2011, pp. 780–788, 10.3945/ajcn.110.005801; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057547/
  35. Wei, Melissa Y., and Terry A. Jacobson. “Effects of Eicosapentaenoic Acid versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis.” Current Atherosclerosis Reports, vol. 13, no. 6, 6 Oct. 2011, pp. 474–483, 10.1007/s11883-011-0210-3; https://pubmed.ncbi.nlm.nih.gov/21975919/
  36. Montori, V. M., et al. “Fish Oil Supplementation in Type 2 Diabetes: A Quantitative Systematic Review.” Diabetes Care, vol. 23, no. 9, 1 Sept. 2000, pp. 1407–1415, 10.2337/diacare.23.9.1407; https://pubmed.ncbi.nlm.nih.gov/10977042/
  37. Eslick, Guy D., et al. “Benefits of Fish Oil Supplementation in Hyperlipidemia: A Systematic Review and Meta-Analysis.” International Journal of Cardiology, vol. 136, no. 1, 24 July 2009, pp. 4–16, 10.1016/j.ijcard.2008.03.092; https://pubmed.ncbi.nlm.nih.gov/18774613/
  38. Oliveira, Julicristie M., and Patrícia H. C. Rondó. “Omega-3 Fatty Acids and Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Systematic Review and Meta-Analysis.” HIV Clinical Trials, vol. 12, no. 5, 1 Sept. 2011, pp. 268–274, 10.1310/hct1205-268; https://pubmed.ncbi.nlm.nih.gov/22180524/
  39. Bernstein, Adam M., et al. “A Meta-Analysis Shows That Docosahexaenoic Acid from Algal Oil Reduces Serum Triglycerides and Increases HDL-Cholesterol and LDL-Cholesterol in Persons without Coronary Heart Disease.” The Journal of Nutrition, vol. 142, no. 1, 1 Jan. 2012, pp. 99–104, 10.3945/jn.111.148973; https://pubmed.ncbi.nlm.nih.gov/22113870/
  40. Barber, Thomas M., et al. “The Health Benefits of Dietary Fibre.” Nutrients, vol. 12, no. 10, 21 Oct. 2020, p. 3209, 10.3390/nu12103209; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589116/
  41. Makki, Kassem, et al. “The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease.” Cell Host & Microbe, vol. 23, no. 6, June 2018, pp. 705–715, 10.1016/j.chom.2018.05.012; https://pubmed.ncbi.nlm.nih.gov/29902436/
  42. Reynolds, Andrew N., et al. “Dietary Fibre and Whole Grains in Diabetes Management: Systematic Review and Meta-Analyses.” PLOS Medicine, vol. 17, no. 3, 6 Mar. 2020, p. e1003053, 10.1371/journal.pmed.1003053; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059907/
  43. Kim, Shana J., et al. “Effects of Dietary Pulse Consumption on Body Weight: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” The American Journal of Clinical Nutrition, vol. 103, no. 5, 1 May 2016, pp. 1213–1223, 10.3945/ajcn.115.124677; https://pubmed.ncbi.nlm.nih.gov/27030531/
  44. Jovanovski E, et al; “Can dietary viscous fiber affect body weight independently of an energy-restrictive diet? A systematic review and meta-analysis of randomized controlled trials”; Am J Clin Nutr. 2020 Feb 1;111(2):471-485. doi: 10.1093/ajcn/nqz292; https://pubmed.ncbi.nlm.nih.gov/31897475/
  45. Rao, S. S. C., et al. “Systematic Review: Dietary Fibre and FODMAP-Restricted Diet in the Management of Constipation and Irritable Bowel Syndrome.” Alimentary Pharmacology & Therapeutics, vol. 41, no. 12, 22 Apr. 2015, pp. 1256–1270, 10.1111/apt.13167; https://pubmed.ncbi.nlm.nih.gov/25903636/
  46. Damas, Felipe, et al. “The Development of Skeletal Muscle Hypertrophy through Resistance Training: The Role of Muscle Damage and Muscle Protein Synthesis.” European Journal of Applied Physiology, vol. 118, no. 3, 27 Dec. 2017, pp. 485–500, doi:10.1007/s00421-017-3792-9. https://pubmed.ncbi.nlm.nih.gov/29282529/
  47. Meloni, A. R., et al. “GLP-1 Receptor Activated Insulin Secretion from Pancreatic β-Cells: Mechanism and Glucose Dependence.” Diabetes, Obesity and Metabolism, vol. 15, no. 1, 1 Aug. 2012, pp. 15–27, doi:10.1111/j.1463-1326.2012.01663.x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556522/
  48. Vincent, John B. “Quest for the Molecular Mechanism of Chromium Action and Its Relationship to Diabetes.” Nutrition Reviews, vol. 58, no. 3, 27 Apr. 2009, pp. 67–72, doi:10.1111/j.1753-4887.2000.tb01841.x. https://pubmed.ncbi.nlm.nih.gov/10812920/
  49. Vincent, John B. “Mechanisms of Chromium Action: Low-Molecular-Weight Chromium-Binding Substance.” Journal of the American College of Nutrition, vol. 18, no. 1, Feb. 1999, pp. 6–12, doi:10.1080/07315724.1999.10718821. https://pubmed.ncbi.nlm.nih.gov/10067653/
  50. Davis, C. Michele, and John B. Vincent. “Chromium Oligopeptide Activates Insulin Receptor Tyrosine Kinase Activity†.” Biochemistry, vol. 36, no. 15, Apr. 1997, pp. 4382–4385, doi:10.1021/bi963154t. https://pubmed.ncbi.nlm.nih.gov/9109644/
  51. Yamamoto, A et al; “Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance.”; Biochemical and biophysical research communications; vol. 163,1; 1989; 189-93.; https://pubmed.ncbi.nlm.nih.gov/2775259/
  52. Davies, Stephen, et al. “Age-Related Decreases in Chromium Levels in 51,665 Hair, Sweat, and Serum Samples from 40,872 Patients—Implications for the Prevention of Cardiovascular Disease and Type II Diabetes Mellitus.” Metabolism, vol. 46, no. 5, May 1997, pp. 469–473, doi:10.1016/s0026-0495(97)90179-7. https://pubmed.ncbi.nlm.nih.gov/9160809/
  53. Kozlovsky, Adriane S., et al. “Effects of Diets High in Simple Sugars on Urinary Chromium Losses.” Metabolism, vol. 35, no. 6, 1 June 1986, pp. 515–518, doi:10.1016/0026-0495(86)90007-7. https://pubmed.ncbi.nlm.nih.gov/3713513/
  54. Anderson, Richard A. “Stress effects on chromium nutrition of humans and farm animals”; Nottingham University Press, England; 1994. https://www.cabidigitallibrary.org/doi/pdf/10.5555/20063209390
  55. Anton, Stephen D., et al. “Effects of Chromium Picolinate on Food Intake and Satiety.” Diabetes Technology & Therapeutics, vol. 10, no. 5, Oct. 2008, pp. 405–412, doi:10.1089/dia.2007.0292. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753428/
  56. Docherty, J et al; “A Double-Blind, Placebo-Controlled, Exploratory Trial of Chromium Picolinate in Atypical Depression: Effect on Carbohydrate Craving.”; Journal of Psychiatric Practice; September 2005; Volume 11, Issue 5; pp 302-314. https://journals.lww.com/practicalpsychiatry/Abstract/2005/09000/A_Double_Blind,_Placebo_Controlled,_Exploratory.4.aspx
  57. Anderson RA et al; “Stability and Absorption of Chromium and Absorption of Chromium Histidinate Complexes by Humans”; Biol Trace Elem Res.; 2004 Dec;101(3):211-8. doi: 10.1385/BTER:101:3:211; https://pubmed.ncbi.nlm.nih.gov/15564651/
  58. DiSilvestro RA and Dy, E. “Comparison of Acute Absorption of Commercially Available Chromium Supplements.”; J Trace Elem Med Bio.; 2007;21(2):120-4. doi: 10.1016/j.jtemb.2007.01.004; https://pubmed.ncbi.nlm.nih.gov/17499152/

Comments and Discussion (Powered by the PricePlow Forum)